A Trial of Grazax in Subjects With Hayfever

This study has been completed.
Information provided by:
ALK-Abelló A/S
ClinicalTrials.gov Identifier:
First received: January 11, 2007
Last updated: June 23, 2015
Last verified: June 2015

January 11, 2007
June 23, 2015
December 2006
August 2007   (final data collection date for primary outcome measure)
Recording of allergy symptoms [ Time Frame: Grass pollen season 2007 ] [ Designated as safety issue: Yes ]
Recording of allergy symptoms
Complete list of historical versions of study NCT00421655 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
A Trial of Grazax in Subjects With Hayfever
A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma
The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.
Not Provided
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Drug: Grazax
Tablets 75,000 SQT and matching placebo. One tablet daily.
  • Experimental: 1
    Intervention: Drug: Grazax
  • Placebo Comparator: 2
    Intervention: Drug: Grazax
Murphy K, Gawchik S, Bernstein D, Andersen J, Pedersen MR. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. J Negat Results Biomed. 2013 Jun 1;12:10. doi: 10.1186/1477-5751-12-10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2007
August 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • History of grass pollen allergy
  • Positive skin prick test to grass
  • Positive specific IgE to grass

Exclusion Criteria

  • FEV1 <70% of predicted value
18 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Kim Simonsen, MD, Senior Director, ALK-Abello
ALK-Abelló A/S
Not Provided
Study Director: Kim Simonsen, MD ALK-Abelló A/S
ALK-Abelló A/S
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP